- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05803811
Efeito da Vitamina B2 Distribuída no Cólon na Microbiota Intestinal e Biomarcadores de Saúde Relacionados em Idosos Saudáveis
The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Cork, Irlanda
- Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
- Between 50 and 70 years of age.
- Has a BMI of between 18.5 - 30 Kg/m2.
- Participants have had a stable body weight (≤5 % change) over the past 3-months.
- Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
- Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
- Maintain current level of physical activity.
- Willing to consume the investigational product daily for the duration of the study.
- Female participants in menopause for at least the last one year. -
Exclusion Criteria:
-
Are hypersensitive to any of the components of the test product.
-
Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)
-
Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.
-
Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).
-
Is a smoker or vaper.
-
Vegetarian or vegan.
-
Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).
-
Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
-
Has a currently active eating disorder.
-
Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.
-
Is having a typical fibre intake >30 g fibre/day.
-
Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.
-
If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.
-
Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.
-
Has a current or history of any gastrointestinal cancer
-
Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).
-
Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).
-
Have a current malignant disease or any concomitant end-stage organ disease.
-
Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
-
Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
-
Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.
-
If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).
-
Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).
-
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Low dose
Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Experimental: Mid dose
Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Experimental: high dose
Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Comparador de Placebo: Placebo
One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Faecal microbial composition
Prazo: from baseline to 12 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12 |
from baseline to 12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Alpha diversity
Prazo: from baseline to 12 weeks
|
Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12. |
from baseline to 12 weeks
|
|
Beta diversity
Prazo: week 0 to week 12
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12 |
week 0 to week 12
|
|
Faecal microbial metabolites fatty acid content at baseline and week 12
Prazo: from baseline to 12 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12 |
from baseline to 12 weeks
|
|
Acetate, Propionate and Butyrate
Prazo: baseline and week 12
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12. |
baseline and week 12
|
|
Intestinal inflammation
Prazo: from baseline to 12 weeks
|
Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12 |
from baseline to 12 weeks
|
|
Intestinal barrier integrity
Prazo: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Oxidative stress in blood
Prazo: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Inflammatory status in blood
Prazo: from baseline to 12 weeks
|
Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12. |
from baseline to 12 weeks
|
|
Gastrointestinal symptoms
Prazo: from baseline to 12 weeks
|
Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12. |
from baseline to 12 weeks
|
|
health-related quality of life
Prazo: from baseline to 12 weeks
|
Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase. |
from baseline to 12 weeks
|
|
Stool consistency
Prazo: from baseline to 12 weeks
|
Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively. |
from baseline to 12 weeks
|
|
Stool frequency
Prazo: from baseline to 12 weeks
|
Stool frequency, as reported in the daily eDiary app (at baseline and week 12). |
from baseline to 12 weeks
|
|
Systemic vitamin status
Prazo: from baseline to 12 weeks
|
The concentration of B vitamins in blood at baseline |
from baseline to 12 weeks
|
|
Faecal physiological pH and redox
Prazo: from baseline to 12 weeks
|
Faecal physiological parameters measured as pH and redox potential at baseline and at week 12. |
from baseline to 12 weeks
|
|
Faecal microbial composition at week 4
Prazo: from baseline to 4 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4. |
from baseline to 4 weeks
|
|
Alpha diversity at week 4
Prazo: baseline to Week 4.
|
Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4. |
baseline to Week 4.
|
|
Beta diversity at week 4
Prazo: week 0 to week 4
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4 |
week 0 to week 4
|
|
Microbial metabolites at week 4
Prazo: from baseline to 4 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4. |
from baseline to 4 weeks
|
|
Acetate, Propionate and Butyrate at week 4
Prazo: week 0 to week 4
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4. |
week 0 to week 4
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Skin barrier integrity
Prazo: from baseline to 12 weeks
|
Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12. |
from baseline to 12 weeks
|
|
Skin hydration
Prazo: from baseline to 12 weeks
|
Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12. |
from baseline to 12 weeks
|
|
Objective skin-health
Prazo: from baseline to 12 weeks
|
Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12. |
from baseline to 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Prof Timothy Dinan, Cork University Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2020-11-11-VITB2
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .